Intrathecal Transplantation of UC-MSC in Patients With Early Stage of Chronic Spinal Cord Injury

Biological/cell based

General health

Online since 4 November 2021, updated 895 days ago

About this trial

This study is recruiting individuals with spinal cord injuries to evaluate the safety and effect of transplanting umbilical cord-derived stem cells (UC-MSC) for treatment of different phases of spinal cord injury: sub-acute (two week to two months); early chronic (two months to 12 months), and late chronic (after 12 months). The purpose is to measure any benefit from UC-MSC transplantation, and to find out the best time for treatment. In the first part of the study, investigators will treat individuals with early stage chronic injuries with UC-MSC transplantation or placebo.

Included participants

Gender

All

Age

18 - 65 years

Injury level

C1 - S5

Severity (AIS)?

AIS-A

AIS-B

AIS-C

AIS-D

Time since injury

2 months - 12 months

Injury type

Traumatic

Healthy volunteers

C1-S5

What’s involved

Type

Biological/cell based

Details

If included, the participant will receive an intrathecal injection of either 1) UC-MSC or 2) placebo (no UC-MSC), into the CSF (cerebrospinal fluid) around the spinal cord, once a month for 4 months. The participant will be followed for 12 months.

Potential benefits

Main benefits

General health

Additional benefits

Arm/hand function

Bladder health/function

Sensory function

Standing/walking/mobility

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results